<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149383</url>
  </required_header>
  <id_info>
    <org_study_id>033-2004</org_study_id>
    <nct_id>NCT00149383</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McLaughlin-Rotman Center for Global Health, University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive
      rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Rationale: Evidence suggests that if PPAR-RXR agonists (such as rosiglitazone) are used
      as adjunctive therapy in P. falciparum malaria infections they may increase phagocytic
      clearance of P. falciparum malaria, modulate deleterious inflammatory responses and decrease
      sequestration of malaria parasites in vital organs. They may therefore represent a novel
      immunomodulatory treatment approach for P. falciparum malaria.

      Study Objectives: 1) To examine the in vivo effect of rosiglitazone on the rapidity of
      clearance of P. falciparum parasitemia and fever in patients with non-severe P. falciparum
      infections 2) To assess the safety and tolerability of adjunctive rosiglitazone treatment in
      non-severe cases of P. falciparum infection.

      Primary Outcomes: Time to clearance of P. falciparum parasitemia

      Study Design: Randomized double blind placebo-controlled trial.

      Intervention: Standard antimalarial treatment (atovaquone/proguanil) to all patients combined
      with adjuvant rosiglitazone treatment (8mg per day) or placebo.

      Setting: Hospital for Tropical Diseases at Mahidol University, Thailand.

      Participants: 140 patients with non-severe P. falciparum infection.

      Follow-up: 28 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clearance (in hours) of parasitemia from blood is recorded</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever (in hours)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST/ALT levels (U/L)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capillary blood glucose (mmol/L)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for ICU admission</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of study drug/placebo as assessed by patient log</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Microscopically confirmed P.falciparum infection

          -  Age &gt;18 years

          -  Able to tolerate oral therapy

          -  Able to give informed consent

        Exclusion Criteria:

          -  Fulfillment of WHO criteria for severe/cerebral malaria

          -  Prior treatment with any thiazolidinedione

          -  Allergy to rosiglitazone

          -  History of diabetes mellitus

          -  History of severe/decompensated liver disease

          -  ALT level &gt;2.5 times normal

          -  Current treatment for congestive heart failure

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin C Kain, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, University of Toronto; McLaughlin-Rotman Center for Global Health, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.tm.mahidol.ac.th</url>
    <description>Mahidol University, Faculty of Tropical Medicine</description>
  </link>
  <link>
    <url>http://www.mcmm.ca</url>
    <description>McLaughlin Centre for Molecular Medicine, McLaughlin-Rotman Center for Global Health</description>
  </link>
  <reference>
    <citation>Suh KN, Kain KC, Keystone JS. Malaria. CMAJ. 2004 May 25;170(11):1693-702. Review.</citation>
    <PMID>15159369</PMID>
  </reference>
  <reference>
    <citation>Patel SN, Serghides L, Smith TG, Febbraio M, Silverstein RL, Kurtz TW, Pravenec M, Kain KC. CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages. J Infect Dis. 2004 Jan 15;189(2):204-13. Epub 2004 Jan 9.</citation>
    <PMID>14722884</PMID>
  </reference>
  <reference>
    <citation>Serghides L, Smith TG, Patel SN, Kain KC. CD36 and malaria: friends or foes? Trends Parasitol. 2003 Oct;19(10):461-9. Review.</citation>
    <PMID>14519584</PMID>
  </reference>
  <reference>
    <citation>Smith TG, Ayi K, Serghides L, Mcallister CD, Kain KC. Innate immunity to malaria caused by Plasmodium falciparum. Clin Invest Med. 2002 Dec;25(6):262-72. Review.</citation>
    <PMID>12516999</PMID>
  </reference>
  <reference>
    <citation>Smith TG, Serghides L, Patel SN, Febbraio M, Silverstein RL, Kain KC. CD36-mediated nonopsonic phagocytosis of erythrocytes infected with stage I and IIA gametocytes of Plasmodium falciparum. Infect Immun. 2003 Jan;71(1):393-400.</citation>
    <PMID>12496189</PMID>
  </reference>
  <reference>
    <citation>Serghides L, Kain KC. Mechanism of protection induced by vitamin A in falciparum malaria. Lancet. 2002 Apr 20;359(9315):1404-6.</citation>
    <PMID>11978340</PMID>
  </reference>
  <reference>
    <citation>Serghides L, Kain KC. Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. J Immunol. 2001 Jun 1;166(11):6742-8.</citation>
    <PMID>11359831</PMID>
  </reference>
  <reference>
    <citation>McGilvray ID, Serghides L, Kapus A, Rotstein OD, Kain KC. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance. Blood. 2000 Nov 1;96(9):3231-40.</citation>
    <PMID>11050008</PMID>
  </reference>
  <reference>
    <citation>Serghides L, Crandall I, Hull E, Kain KC. The Plasmodium falciparum-CD36 interaction is modified by a single amino acid substitution in CD36. Blood. 1998 Sep 1;92(5):1814-9.</citation>
    <PMID>9716613</PMID>
  </reference>
  <reference>
    <citation>Urquhart AD. Putative pathophysiological interactions of cytokines and phagocytic cells in severe human falciparum malaria. Clin Infect Dis. 1994 Jul;19(1):117-31. Review.</citation>
    <PMID>7948512</PMID>
  </reference>
  <reference>
    <citation>Ockenhouse CF, Ho M, Tandon NN, Van Seventer GA, Shaw S, White NJ, Jamieson GA, Chulay JD, Webster HK. Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis. 1991 Jul;164(1):163-9.</citation>
    <PMID>1711552</PMID>
  </reference>
  <reference>
    <citation>Ockenhouse CF, Chulay JD. Plasmodium falciparum sequestration: OKM5 antigen (CD36) mediates cytoadherence of parasitized erythrocytes to a myelomonocytic cell line. J Infect Dis. 1988 Mar;157(3):584-8.</citation>
    <PMID>2449507</PMID>
  </reference>
  <reference>
    <citation>Oquendo P, Hundt E, Lawler J, Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell. 1989 Jul 14;58(1):95-101.</citation>
    <PMID>2473841</PMID>
  </reference>
  <reference>
    <citation>Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, Mai NT, Phu NH, Sinh DX, White NJ, Ho M. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis. 1999 Oct;180(4):1288-97.</citation>
    <PMID>10479160</PMID>
  </reference>
  <reference>
    <citation>Kwiatkowski D, Hill AV, Sambou I, Twumasi P, Castracane J, Manogue KR, Cerami A, Brewster DR, Greenwood BM. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet. 1990 Nov 17;336(8725):1201-4.</citation>
    <PMID>1978068</PMID>
  </reference>
  <reference>
    <citation>Brown H, Turner G, Rogerson S, Tembo M, Mwenechanya J, Molyneux M, Taylor T. Cytokine expression in the brain in human cerebral malaria. J Infect Dis. 1999 Nov;180(5):1742-6.</citation>
    <PMID>10515846</PMID>
  </reference>
  <reference>
    <citation>Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, McKeigue PM, Kwiatkowski D, Greenwood BM, Snow RW, Hill AV, Scott J. Malaria susceptibility and CD36 mutation. Nature. 2000 Jun 29;405(6790):1015-6.</citation>
    <PMID>10890433</PMID>
  </reference>
  <reference>
    <citation>Omi K, Ohashi J, Naka I, Patarapotikul J, Hananantachai H, Looareesuwan S, Tokunaga K. Polymorphisms of CD36 in Thai malaria patients. Southeast Asian J Trop Med Public Health. 2002;33 Suppl 3:1-4.</citation>
    <PMID>12971464</PMID>
  </reference>
  <reference>
    <citation>Shankar AH, Genton B, Semba RD, Baisor M, Paino J, Tamja S, Adiguma T, Wu L, Rare L, Tielsch JM, Alpers MP, West KP Jr. Effect of vitamin A supplementation on morbidity due to Plasmodium falciparum in young children in Papua New Guinea: a randomised trial. Lancet. 1999 Jul 17;354(9174):203-9.</citation>
    <PMID>10421302</PMID>
  </reference>
  <reference>
    <citation>Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet. 2000 Mar 18;355(9208):1008-10.</citation>
    <PMID>10768450</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized controlled trial</keyword>
  <keyword>malaria</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>thiazolidinediones</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>atovaquone-proguanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

